



HAL
open science

Use of bacterial magnetosomes in the magnetic hyperthermia treatment of tumours: A review

Edouard Alphan  ry, Im  ne Chebbi, Fran  ois Guyot, Micka  l Durand-Dubief

► To cite this version:

Edouard Alphan  ry, Im  ne Chebbi, Fran  ois Guyot, Micka  l Durand-Dubief. Use of bacterial magnetosomes in the magnetic hyperthermia treatment of tumours: A review. *International Journal of Hyperthermia*, 2013, 29 (8), pp.801-809. 10.3109/02656736.2013.821527 . hal-01548968

HAL Id: hal-01548968

<https://hal.sorbonne-universite.fr/hal-01548968>

Submitted on 28 Jun 2017

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destin  e au d  p  t et    la diffusion de documents scientifiques de niveau recherche, publi  s ou non,   manant des   tablissements d'enseignement et de recherche fran  ais ou   trangers, des laboratoires publics ou priv  s.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Use of bacterial magnetosomes in the magnetic hyperthermia treatment of tumors: A review.

Edouard Alphandéry^{+,-,*}, Imène Chebbi⁺, François Guyot[⊥], Mickaël Durand-Dubief⁺

⁺ Nanobacterie SARL, 36 boulevard Flandrin, 75016, Paris, France.

[⊥] IMPMC, UPMC, 4 place Jussieu, 75005, Paris, France.

*Corresponding author: Edouard Alphandéry (edouardalphandery@hotmail.com)

1
2
3 *Introduction:*
4

5
6 Magnetic hyperthermia is a method used for treating cancers in which iron oxide nanoparticles are
7 administered (or sent) to tumors and heated under the application of an alternating magnetic field.
8

9
10 The heat produced by the nanoparticles induces anti-tumor activity. To date, most nanoparticles
11 tested pre-clinically, [1-3], and clinically, [4], were chemically synthesized, mainly in the form of
12 superparamagnetic iron oxide nanoparticles (SPION). However, SPION possess a series of drawbacks,
13 including a thermally unstable magnetic moment that yields non-optimized magnetic properties;
14 they are small in size which usually result in the production of a small amount of heat under the
15 application of an alternating magnetic field and they tend to aggregate which can cause toxicity *in*
16 *vivo*. Such drawbacks can be avoided by using biologically synthesized nanoparticles, called
17 magnetosomes, which are produced by several strains of a species of bacteria, called magnetotactic
18 bacteria, MTB, [5]. Magnetosomes are large monodomain ferrimagnetic nanoparticles, which are
19 composed of a core of crystallized maghemite or magnetite surrounded by biological material
20 essentially made of lipids and proteins. They are usually arranged in chains and are used by MTB as a
21 compass to navigate in the direction of the earth magnetic field. There are essentially two features
22 that make the magnetosomes appealing for the magnetic hyperthermia treatment of tumors: (i) their
23 large size and ferrimagnetic behavior enable the production of a large amount of heat when they are
24 exposed to an alternating magnetic field and (ii) their arrangement in chains prevents aggregation,
25 yields a high rate of cellular internalization and enables uniform heating throughout the tumor, [6, 7].
26
27

28
29 Here, we review the most recent and significant results published in the field of MTB in particular
30 data relating to the use of bacterial magnetosomes in magnetic hyperthermia for the treatment of
31 tumors. We review different methods for cultivating MTB and preparing suspensions of bacterial
32 magnetosomes. As well as the production of magnetosomes, we also review key data on the toxicity
33 of the magnetosomes as well as their heating and anti-tumor efficiencies. The toxicity and efficiency
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

of magnetosomes needs to be understood and to measure the risk-benefit ratio, with which to evaluate their use in the magnetic hyperthermia treatment of tumors.

1. Culture of MTB and preparation of the magnetosomes

1.1 Culture of magnetotactic bacteria:

There are several species of MTB that can be cultivated including both marine and freshwater bacteria (MS-1, MV-1, MSR-1 and AMB-1). In this review, we describe the methods used for the growth of the most widely studied and commercially available strains, *Magnetospirillum Sp.* MSR-1 and AMB-1 MTB (MSR-1 DSMZ-6361 and AMB-1 ATCC-700264). The optimization of the growth of *Magnetospirillum gryphiswaldense* MSR-1 MTB has been described in a series of three successive publications, [8-10]. First, MSR-1 MTB were cultivated in growth medium containing magnesium sulfate ($MgSO_4$), sodium thioglocate, yeast extracts, minerals, ferric citrate, ammonium chloride (NH_4Cl) and sodium lactate in a 42 L fermentor, [8]. This medium was inoculated with 4.2 L of MSR-1 MTB suspension. During growth, the pH was maintained at 7 using fed-batch conditions in which a solution containing sodium lactate, NH_4Cl and ferric citrate was added to the growth medium. These conditions enabled maintenance of a sustainable growth rate for the bacteria. The concentration of dissolved oxygen (DO) in the growth medium, which is an important parameter that influences both the growth rate of the bacteria and the magnetosome production yield, was kept below 10% oxygen saturation to enhance the cell biomass. The production of magnetosomes was then triggered by reducing the DO concentration to 1% oxygen saturation. Such low DO values were obtained by progressively increasing the stir rate from 100 rpm up to 300 rpm during the growth of the bacteria, while sterile air was bubbled through the growth medium at a low speed of 0.3 L/min. These conditions allowed the synthesis of a high number of magnetosomes per bacterium (~ 25) and the production of a large percentage of magnetosomes containing cells (between 90 and 100 %). After 60 hours of growth, the magnetosome production yield and the magnetosome productivity for MSR-1

1
2
3 were 42 mg/L and 17 mg/L/day respectively. This growth protocol was further optimized by using a
4
5 different method for more accurate control of the percentage of oxygen contained within the
6
7 fermentor, [9]. This was achieved by changing both the stir rate and the air flow during the growth of
8
9 the bacteria. After 36 hours of bacterial growth, the magnetosome production yield a magnetosome
10
11 productivity increased to 83 mg/L and 55 mg/L/day respectively, [9]. A second improvement was
12
13 achieved by replacing the sources of carbon and nitrogen in the bacterial growth medium to avoid
14
15 the accumulation of sodium and chloride ions, which are toxic for non-marine species of MTB such as
16
17 MSR-1 and inhibit high cell concentrations, [10]. Under these conditions, after 36 hours of growth,
18
19 the magnetosome production yield and magnetosome productivity further increased to 168 mg/L
20
21 and 68 mg/L/day, respectively. Another method used to cultivate MSR-1 MTB, not involving fed-
22
23 batch conditions, yielded a rapid production of magnetosomes in 4 hours and a magnetosome
24
25 productivity of 6.3 mg/L/hour and 151/mg/L/day, [11]. This method has the advantage of being
26
27 simpler and therefore more practicable for the industrial production of MTB under good
28
29 manufacturing practice (GMP) conditions. For the growth of AMB-1 MTB, it has been shown that it is
30
31 possible to grow these bacteria in a large 1000 liters fermentor which can produce 2.6 g of
32
33 magnetosomes after 7 days, [12]. In this study, the growth medium was completely saturated with
34
35 nitrogen gas, [12]. As for MSR-1 MTB, AMB-1 MTB were also cultivated in fed-batch conditions.
36
37 These bacteria were grown in a 4 L fermentor in ATCC medium 1653 and maintained at pH 6.75 by
38
39 adding nitric acid solution. This enabled a magnetosome production yield of 4.5 mg/L, [13]. This
40
41 growth protocol was further optimized by changing the feeding solution and the source of iron, [14].
42
43 AMB-1 MTB were cultivated in a 10 L fermentor with a pH-stat system. The feeding solution
44
45 contained succinic acid, sodium nitrate, and nitric acid. Iron gallate and iron sulfate were the iron
46
47 sources found to give the most optimum yield of magnetosome production. The oxygen
48
49 concentration was maintained between 9 and 15% in the gas phase, which was found to be the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 optimum oxygen concentration for magnetosome production. Under these conditions, the
4
5 magnetosome production yield reached 15 mg/L, [14].
6
7

8 The optimizations of the growth conditions described above will enable industrial developments,
9
10 which require the production of a large quantity of magnetosomes. These large volumes can indeed
11
12 be obtained either by using a growth method that yields high level of magnetosomes via the
13
14 cultivation of MSR-1 MTB, [10], or by the culture of MTB in large volumes, [12]. In this regard, iron
15
16 chelating agents such as hemoglobin, EDTA and rhodamine, could be introduced into the bacterial
17
18 growth medium to enhance the growth rate of magnetotactic bacteria and to increase the
19
20 magnetosome production yield, [15]. For example, introducing 0.4 μ M of hemoglobin solution into
21
22 the growth medium of AMB-1 MTB, increased the quantity of magnetosomes produced by a factor of
23
24 ~ 8 , [15]. Finally, reasonably high magnetosome productivity of 6.3 mg/L/hour has been achieved
25
26 under batch conditions, which are more favorable in an industrial setting than fed-batched
27
28 conditions, [11].
29
30
31

32 *1.2 Isolation of the magnetosomes from the magnetotactic bacteria:*

33
34

35 There are two reasons why suspensions of MTB could not be used for magnetic hyperthermia
36
37 treatments of cancers: (i) the concentration of magnetosomes in a suspension of MTB is too low and
38
39 results in poor heating efficiency and thus absence of any anti-tumor activity, [6], and (ii) health and
40
41 safety issues preventing the administration of whole MTB into humans. To be used in cancer therapy,
42
43 the magnetosomes must therefore be isolated from the MTB. The methods used in the preparation
44
45 of these isolated magnetosomes are described below. To extract the magnetosomes from MTB, four
46
47 main techniques have been tested, which use sodium hydroxide (NaOH), sonication, a French press
48
49 or a pressure homogenizer to lyse the bacterial cells. The first tested method involved the mixing of
50
51 MSR-1 MTB with a 5 M NaOH solution for approximately 16 hours before their centrifugation for 10
52
53 hours at 8000 rpm to separate the magnetosomes from the debris of bacterial cells, [16]. This
54
55
56
57
58
59
60

1
2
3 seemed to have resulted in magnetosomes organized in chains, clumps and loops, [16]. The second
4
5 involved sonications at 300 W for 15 minutes, [17], 80 W for 10 minutes, [18], or 30 W for two hours,
6
7 [6], to lyse MSR-1, MS-1 and AMB-1 MTB, respectively. Using this method, the highest sonication
8
9 power led to the extraction of aggregated magnetosomes, [17], and the lowest sonication power
10
11 gave well dispersed chains of magnetosomes, [6, 18]. The third test, involving the passing of
12
13 suspensions of MTB two to three times through a French press at a pressure of 1000-20 000 lb/in² to
14
15 lyse AMB-1, [19], and MSR-1, [20, 21], MTB resulted in aggregated magnetosomes [20, 21]. Finally, a
16
17 pressure homogenizer has also been used to lyse MSR-1 MTB, [22, 23] at a pressure of 9000-18000
18
19 lb/in², [23]. While this method does preserve the magnetosome membrane, [23], on which
20
21 magnetosome organization depends, [24], only a few transmission electron microscopic images of
22
23 the magnetosomes isolated using this method have been published making it difficult to confirm
24
25 with certainty the magnetosome organization, [22, 23]. The technique used to lyse the cells, which
26
27 produces different levels of bacterial cell disruption, does affect the magnetosome organization, [24].
28
29
30
31

32 *1.3 Purification of the suspension of magnetosomes:*

33
34

35 Following extraction of the magnetosomes from whole MTB, several different methods have been
36
37 suggested for their purification. One of the most comprehensive methods described involved a
38
39 system of magnetic isolation followed by low power ultrasonication and treatment with urea;
40
41 treatment with proteinase K to remove adsorbed and surface proteins and with electro-elution to
42
43 remove nucleic acids, [22]. The magnetosomes were then lyophilized and sterilized with gamma rays,
44
45 [22]. Other techniques have used phenylmethylsulfonyl fluoride to inhibit the activity of the
46
47 protease; a MACS magnetic column to wash the suspension of magnetosomes with Hepes buffer,
48
49 [25], and a treatment with 5 µg/ml of DNase I for two hours to remove DNA, [26]. To examine if the
50
51 purification was successful, the suspension of magnetosomes was centrifuged and the absorption of
52
53 the supernatant was measured at 280 nm. Therefore, the amount of biological material remaining in
54
55 the supernatant could be quantified. A successful purification method would lead to a only a small
56
57
58
59
60

1
2
3 quantity of biological material remaining in the supernatant and therefore a low absorbance, [27].
4
5 The percentage of magnetosomes obtained from 1 g of cells depends on the extraction and
6
7 purification methods used and ranges between 0.6 % and 4 %, [20, 25, 27].
8
9

10 *1.4 Characterization of the suspension of magnetosomes:*

11

12
13 Characterization of the magnetosome suspension is another important aspect to be considered.
14
15 Indeed, before administering a suspension of magnetosomes to humans, its full characterization is
16
17 first required. The biological material surrounding magnetosomes, which is essentially made of fatty
18
19 acids, phospholipids and proteins, has been mainly characterized using chromatography, infra-red
20
21 spectroscopy, SDS-page and mass spectroscopy. Previous studies have shown that around 18
22
23 proteins were surround the magnetosomes in the MSR-1 species, representing 4% of the total
24
25 weight, [25]. Lipids represent a higher percentage of the total weight of the magnetosomes, (~ 17%),
26
27 consisting of 1.4% of neutral lipids and free fatty acids, 5.1% of glycolipids, sulfolipids and
28
29 phosphatides and 10.5% of phospholipids, [27]. The concentration of the magnetosome suspension,
30
31 which needs to be known before administration, has been estimated previously using optical density
32
33 at 650 nm, [19], or 480 nm, [6], and by a using a destructive assay that measures the iron
34
35 concentration in the suspension, [6]. Transmission electron microscopy has been used to measure
36
37 the sizes of the magnetosome cores, which are made of crystallized iron oxide and range between 20
38
39 and 120 nm, [5]. For AMB-1 and MSR-1 species, the sizes of most the magnetosomes range between
40
41 30 and 50 nm and the magnetosomes usually possess a cubooctahedral geometry. The composition
42
43 of the magnetosome core has been reported to be either magnetite, maghemite or intermediate
44
45 between magnetite and maghemite depending on the level of exposure of the magnetosomes to
46
47 oxygen, [28]. Magnetic measurements were used to distinguish between these two compositions by
48
49 measuring the presence (or not) of the Verwey transition, which revealed the presence (or not) of
50
51 magnetite in the magnetosome core, [28].
52
53
54
55
56
57
58
59
60

1
2
3 2. *Magnetosome toxicity and biodistribution*
4

5
6 2.1 *Cytotoxicity of the magnetosomes:*
7

8
9 Cytotoxicity, acute toxicity and immunotoxicity of the bacterial magnetosomes have been assessed
10 and the magnetosome biodistribution has been studied following both intravenous and intratumoral
11 routes of administration. These studies were carried out using bacterial magnetosomes isolated from
12 MTB and then purified.
13
14

15
16
17
18 2.2 *Acute toxicity of the magnetosomes:*
19

20
21 Despite their bacterial origin, suspensions of magnetosomes have shown little cytotoxic effects on
22 mouse fibroblast, H22, HL60 and EMT-6 cells, (29). It was found that 9 µg/mL of bacterial
23 magnetosomes was not toxic for H22, HL60 and EMT-6 cells. For mouse fibroblast cells incubated in
24 the presence of various concentrations of suspensions of bacterial magnetosomes, no cytotoxicity
25 was observed at a magnetosome concentration below 1.3 mg/mL, [21]. Bacterial magnetosomes
26 incubated with MDA-MB-231 cells did not induce cell death or a significant cell inhibition at a
27 magnetosome concentration below 125 µg/mL, (6).
28
29

30
31 The acute toxicity of magnetosomes has also been studied in mice and rats. Suspensions of
32 magnetosomes at doses of 270, 360 or 480 mg/kg were injected intravenously. All mice survived
33 except those treated with the highest dose of magnetosomes, i.e. ~ 0.5% of body weight. In
34 comparison, the mice treated with standard chemical SPION began to die after a lower dose of
35 nanoparticles injected at 135 mg/kg, [30]. In another study, suspensions of magnetosomes were
36 administered to rats intravenously. The rats survived when less than 82 mg/kg of magnetosomes
37 were administered, [29]. However, for the rats that died in this study (when administered with more
38 than 82 mg/kg of magnetosomes), it was reported that their death may have been accidental, due to
39 bacterial infection and not to the administration of the magnetosome suspension. Histological
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 analysis of the main organs (heart, liver, spleen, lung, kidney, brain, intestines, lymph glands and
4
5 thymus) indicated the absence of hemorrhage, inflammation and hyperemia in the rats treated with
6
7 less than 82 mg/kg of bacterial magnetosomes.
8
9

10 *2.3 Immuno-toxicity of the magnetosomes:*

11
12
13 The toxicity of magnetosomes is not likely to be due to iron chemical toxicity since Fe_3O_4 is relatively
14
15 insoluble. While dissolved iron ions may be toxic due to a Fenton reaction, which leads to the
16
17 formation of hydroxyl radicals that are strong oxidants, Fe_3O_4 does not produce the same toxic
18
19 effect. Indeed, the magnetosomes are not reported to trigger the Fenton reaction. They even seem
20
21 to produce the opposite effect by scavenging reactive oxygen species, [31]. The toxicity of
22
23 magnetosomes could also be due to their nanometric sizes that might result in embolism, blood clot,
24
25 cell toxicity or acute toxicity as described above. On the other hand, it could also arise from the
26
27 magnetosome biological impurities, such as the proteins, the nucleic acids and the
28
29 lipopolysaccharides (LPS) surrounding the magnetosomes that could lead to potential
30
31 immunotoxicity, [32]. The latter was studied by administering a 1 mg suspension of magnetosomes
32
33 into the ears of rabbits and then monitoring body temperatures after the injection, [29]. Body
34
35 temperature did not increase suggesting the absence of a pyrogenic effect. Moreover, intravenous
36
37 administration of 40 mg/kg magnetosome suspension into rats revealed no difference in the number
38
39 of white blood cells and lymphocytes to those in untreated rats. The stimulation index of lymphocyte
40
41 cells, which is the ratio between the number of proliferating T lymphocytes present in a lymphocyte
42
43 culture after exposure to antigen to the total number of cells, was also measured for the rats treated
44
45 (or untreated) with an intravenous administration of a suspension of bacterial magnetosomes using
46
47 LPS as antigens. No difference was observed in the stimulating index between the treated and
48
49 untreated rats indicating the absence of immunotoxicity induced by the intravenous injection of 40
50
51 mg/kg of bacterial magnetosomes, [29]. Together, these results indicate that if purified correctly, the
52
53 magnetosomes do not induce side effects and are of low toxicity.
54
55
56
57
58
59
60

2.4 Magnetosome biodistribution:

Studies have also been carried out in mice and rats to investigate the biodistribution of magnetosomes following either an intravenous or an intratumoral route of administration. Their aims were to examine the possible degradation of the magnetosomes and to determine the elimination pathways. First studied was the potential decomposition of magnetosomes by lysosomes, known to degrade nanoparticles. For this, a suspension of magnetosomes isolated from MTB was mixed with crude protease from bovine pancreas that simulates intracellular lysosomal conditions, [26]. The magnetosomes appeared to be degraded after 28 days, suggesting that lysosomes are indeed able to degrade magnetosomes, [33]. The decomposition of magnetosomes by lysosomes was further confirmed by two experimental results. Firstly, suspensions of bacterial magnetosomes were administered to rats, [34], or mice, [23, 33], and their localization was determined by fluorescence microscopy, [23], or histological analysis of the main organs, [33, 34], one to fourteen days following administration. Magnetosomes were found in the liver [33, 34], spleen, [33], and lungs, [23], where they were located inside lysosomes in a partly degraded state. In these studies, the magnetosomes that ended up in the liver and spleen were digested by lysosomes, [33, 34]. Secondly, another study showed that three days following intravenous injection the magnetosomes were neither found in the feces nor in the urine, [34]. These results seem to indicate that the magnetosomes were degraded by the mice or rats. The hypothesis proposed in light of these results was that the reticuloendothelial system, composed of liver and spleen macrophages, removes magnetosomes from the bloodstream, [33]. Other studies, however, have found magnetosomes in the feces of mice following both intratumoral and intravenous routes of administrations, [6, 32]. Taken together, these results suggest that a portion of the bacterial magnetosomes is probably degraded while another portion is eliminated in the feces. Biodistribution studies of chemically synthesized nanoparticles revealed different features. For example, long-term follow up over a period of 6 months of chemically synthesized nanoparticles injected intravenously showed that these nanoparticles were metabolized in the organ's parenchyma

1
2
3 with metal ions leaking from the core material, [35]. However, there are still too few results
4
5 published on the magnetosome biodistribution to be able to compare in details the biodistribution of
6
7 the magnetosomes with that of chemically synthesized nanoparticles. Moreover, further studies are
8
9 necessary to determine more precisely the elimination and degradation pathways of bacterial
10
11 magnetosomes and to examine whether or not the magnetosomes are metabolized.
12

13 14 3. *Magnetic hyperthermia treatment of tumors with magnetosomes:* 15

16 17 3.1 *Heating properties of the magnetosomes:* 18 19

20 Bacterial magnetosomes are good candidates to carry out magnetic hyperthermia since they produce
21
22 a large amount of heat when exposed to an alternating magnetic field. In this review, we report
23
24 values of magnetosome losses per cycle as a measurement of the amount of heat produced by
25
26 magnetosomes. The magnetosome loss per cycle is defined as the magnetosome specific absorption
27
28 rate (SAR) divided by the frequency of oscillation of the alternating magnetic field, where the SAR is
29
30 usually estimated using the formula $SAR = \rho_s C_s (\Delta T / \delta t) / C_{Fe}$, where ρ_s , C_s and C_{Fe} are the density,
31
32 calorific capacity and iron concentration of the sample respectively and $\Delta T / \delta t$ is the slope of the
33
34 variation in temperature with time estimated at the beginning of the heat treatment, [36]. Using loss
35
36 per cycle is convenient since it enables comparison between SAR obtained for different alternating
37
38 magnetic field frequencies. The production of a large amount of heat by the magnetosomes is due to
39
40 their large sizes and ferrimagnetic behavior at physiological temperatures. Indeed, since the
41
42 magnetosomes are monodomain, ferrimagnetic and of cubic shape, the amount of heat that they
43
44 produce is proportional to their sizes. In addition, due to their thermally stable magnetic moment,
45
46 the magnetosomes produce a larger amount of heat than the smaller superparamagnetic chemically
47
48 synthesized nanoparticles. These behaviors have been shown both experimentally and theoretically,
49
50 [36-42]. For suspensions of magnetosomes exposed to a magnetic field of 6.2 mT, losses per cycles of
51
52 0.1-0.2 J/Kg were reported, [36-40]. When the strength of the magnetic field was increased to 12 mT,
53
54
55
56
57
58
59
60

1
2
3 the losses per cycles increased to 0.5-1 J/Kg (33, 37-39), showing that the magnetosome loss per
4
5 cycle strongly increases with increasing magnetic field strength. By comparison with chemically
6
7 synthesized nanoparticles, these losses per cycle are considerably larger at magnetic field strengths
8
9 below 10 mT; and either equivalent, [40], or larger at magnetic field strengths above 10 mT, [41]. The
10
11 heating mechanisms of bacterial magnetosomes have also been studied. Three different types of
12
13 sample were prepared containing whole MTB, chains of magnetosomes extracted from AMB-1 MTB
14
15 or individual magnetosomes detached from the chains by heat and SDS treatments, [41]. Figure 1
16
17 shows transmission electron microscopy images of whole MTB (Figure 1(a)), chains of magnetosomes
18
19 extracted from MTB (Figure 1(b)) and individual magnetosomes (Figure 1(c)). When suspensions of
20
21 whole AMB-1 MTB were mixed with water and exposed to an alternating magnetic field frequency of
22
23 108 KHz and strength of 23 to 88 mT, the losses per cycle ranged between 1.1 and 8 J/Kg_{Fe} and the
24
25 heat released by the magnetosomes was found to mainly arise from the inversion of the
26
27 magnetosome magnetic moment under the application of an alternating magnetic field (magnetic
28
29 viscosity). Indeed, it has been demonstrated that the contribution of the rotation of the whole
30
31 bacteria to the production of heat was negligible, [41]. When the magnetosomes were extracted
32
33 from whole MTB either as chains or individual nanoparticles, the heat released by the magnetosomes
34
35 was reported to arise both from the inversion of the magnetosome magnetic moment (magnetic
36
37 viscosity) and from the magnetosome rotation (hydrodynamic viscous coupling of the medium).
38
39 Consequently, under the application of the same magnetic field strengths, the losses per cycle
40
41 increased considerably to 5-11 J/Kg_{Fe} compared with the values obtained using whole bacteria. It was
42
43 not possible to determine from this study alone if the magnetosome chains or the individual
44
45 magnetosomes would be the best candidate to carry out magnetic hyperthermia treatment of
46
47 tumors since both types of magnetosomes led to high heating efficiencies. The influence on the
48
49 heating properties of the magnetosome size and magnetosome magnetic anisotropy has also been
50
51 studied, [15, 30]. To increase the magnetosome magnetic anisotropy, a 2 μM solution of cobalt
52
53
54
55
56
57
58
59
60

1
2
3 quinate was introduced in the bacterial growth medium resulting in an increase in the
4
5 magnetocrystalline anisotropy constant by a factor of ~ 9 from $K_{\text{eff}} = 12 \text{ KJ/m}^3$ in the absence of cobalt
6
7 up to $K_{\text{eff}} = 104 \text{ KJ/m}^3$ in the presence of cobalt quinate, [30]. This increase in magnetosome
8
9 magnetic anisotropy resulted in an increase in the SAR, [30]. To increase magnetosome sizes, iron
10
11 chelating agents such as EDTA and rhodamine B were introduced in the bacterial growth medium.
12
13 This resulted in an increase of the mean magnetosome sizes from 42.5 nm in the absence of iron
14
15 chelating agents up to 60-65 nm in the presence of rhodamine B or EDTA that produced an
16
17 enhancement of the magnetosome heating properties, [15].
18
19

20 21 3.2 *Antitumor activity of the magnetosomes:* 22

23
24 Although bacterial magnetosomes belong to a type of iron oxide nanoparticles that produces a large
25
26 amount of heat when exposed to an alternating magnetic field, [6, 36-41], the anti-tumor activity
27
28 resulting from a magnetic hyperthermia treatment has to our knowledge only been evaluated in two
29
30 studies, [6, 33]. When MCF-7 tumor cells were mixed with bacterial magnetosomes and heated
31
32 under the application of an alternating magnetic field to reach a temperature of 47 °C, 80% of the
33
34 cell proliferation was inhibited, [33]. It was also mentioned in this study that a temperature of 47 °C
35
36 inhibited more MCF-7 tumor cells than normal L929 cells. This result further supports the safety of
37
38 the treatment. Indeed, it suggests that if during the course of a magnetic hyperthermia treatment
39
40 healthy tissues are heated by mistake, the heat would be less damaging to healthy tissues than to
41
42 tumor tissues. MDA-MB-231 tumor cells were also incubated with a suspension of magnetosomes
43
44 and exposed to an alternating magnetic field under various conditions, [6]. The percentage of cell
45
46 death and cell inhibition increased with increasing concentrations of magnetosomes, increasing
47
48 incubation times, magnetic field strength and the number of times that the heat treatment was
49
50 repeated. This suggests that an efficient treatment can be achieved provided optimum values of
51
52 these four parameters are chosen.
53
54
55
56
57
58
59
60

1
2
3 We performed a proof of concept study for the therapy on breast tumors xeno-grafted under the
4 skin of mice, [6]. Four different types of suspensions were tested containing whole MTB (Figure 1(a)),
5 magnetosomes organized in chains (Figure 1(b)), individual magnetosomes (Figure 1(c)) and SPION.
6
7 Each suspension contained 10 mg/mL of iron oxide and 100 μ L of each suspension was administered
8
9 with a syringe into the center of the xeno-grafted breast tumors ($\sim 100 \text{ mm}^3$ in size) The mice were
10
11 then exposed three times during twenty minutes to an alternating magnetic field strength of 40 mT
12
13 and frequency of 198 kHz. The schematic diagram in Figure 2(a) shows the set-up used for the
14
15 treatment using an induction system that generates an alternating magnetic field. The treatments,
16
17 which used the suspensions of whole MTB, individual magnetosomes and SPION, were inefficient and
18
19 were unable to stop the growth of the tumor. In contrast, when the heat treatment was carried out
20
21 using suspensions of chains of magnetosomes, the tumors in several mice disappeared. Figure 2(b)
22
23 shows a mouse during the treatment. Typical temperatures reached during the treatment with the
24
25 chains of magnetosomes were around 45-46 $^{\circ}\text{C}$ as estimated by infra-red measurements (Figure
26
27 2(b)). Thirty days following the treatment, the tumor had disappeared in the mouse treated with the
28
29 chains of magnetosomes (Figure 2(c)), while it was still located at the skin surface of the mice treated
30
31 with individual magnetosomes (Figure 2(d)) or SPION (Figure 2(e)). We can conclude from these
32
33 results that the efficiency of the bacterial magnetosomes is not only due to their large sizes but also
34
35 comes from their arrangement in chains. When the magnetosomes are organized in chains, they are
36
37 less prone to aggregation. Indeed, several chains of magnetosomes interact in a head to tail manner
38
39 in such a way that they form a longer chain. This behavior can clearly be observed in Figure 1. In
40
41 Figure 1(a), the chains of magnetosomes contained inside the magnetotactic bacterium are short,
42
43 containing ~ 10 magnetosomes. After extraction from the magnetotactic bacteria, the chains of
44
45 magnetosomes are much longer, containing typically more than ~ 20 magnetosomes (Figure 1(b)).
46
47 By contrast, when the magnetosomes are not organized in chains, they tend to form compactly
48
49 aggregated assemblies of individual magnetosomes. This has been shown by studying the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 organization of individual magnetosomes obtained by heat and SDS treatments, [6], or by genetic
4
5 manipulations of magnetotactic bacteria that led to the removal of the filament binding the
6
7 magnetosomes together in a chain inside MTB, [43].
8
9

10 We then examined the impact of the organization in chains of the magnetosomes on the heating and
11
12 distribution uniformity as well as on cellular internalization, [6,7]. The heating uniformity was studied
13
14 by infrared measurements and histological analysis, which showed a more uniform heating and
15
16 distribution throughout the tumor for the chains of magnetosomes than for the individual
17
18 magnetosomes. The internalization of the chains of magnetosomes inside the cells was observed by
19
20 two types of measurements. The chains of magnetosomes were mixed with MDA-MB-231 cells and
21
22 exposed to an alternating magnetic field which resulted in the formation of magnetic cells 5 minutes
23
24 after the beginning of the treatment. Figure 3(a) shows an eppendorf containing MDA-MB-231 cells
25
26 mixed with chains of magnetosomes being exposed to the alternating magnetic field. Before the
27
28 application of the alternating magnetic field, Figure 3(b) shows that the cells are not attracted by a
29
30 magnet positioned next to the eppendorf and are therefore non-magnetic. Therefore, only a small
31
32 black spot located next to the magnet is visible corresponding to magnetosomes without cells being
33
34 attracted by the magnet. By contrast, after the application of the alternating magnetic field, as
35
36 shown in Figure 3(c), a large dark spot appeared next to the magnet relating to the magnetic cells
37
38 attracted by the magnet. MDA-MB-231 cells were also incubated in the presence of the chains of
39
40 magnetosomes for 1 minute and 24 hours using Prussian blue, which reveals the presence of iron.
41
42 Figures 3(d) shows the absence of magnetosome internalization after one minute and an efficient
43
44 internalization after 24 hours of incubation (Figure 3(e)). These results indicate that both the
45
46 application of the alternating magnetic field and the incubation of magnetosomes for a long period
47
48 of time cause high cellular internalization. Histological analysis of the tumor tissues revealed the
49
50 presence of aggregated magnetosomes in the mice treated with individual magnetosomes (Figure
51
52 4(a)) whereas magnetosomes internalized within the cells were observed only in the mice treated
53
54
55
56
57
58
59
60

1
2
3 with suspensions of chains of magnetosomes, (Figures 4(b) and 4(c)). We concluded that uniform
4 heating, uniform magnetosome distribution as well as effective cellular internalization were
5 responsible for the high anti-tumoral efficiency observed with the chains of magnetosomes. The
6 large sizes of the magnetosomes, which yield high values of the SAR, are not sufficient to produce
7 high anti-tumor activity. The distribution of the magnetosomes in the tumor is another key
8 parameter that influences the efficiency of the treatment.
9
10
11
12
13
14

15 16 17 3.3 *Comparison between the chains of magnetosomes and the individual magnetosomes:*

18
19
20 Chains of magnetosomes have been defined as assemblies of magnetosomes in which the
21 crystallographic directions of most of the magnetosomes are aligned in the direction of the chain
22 elongation, [44]. Individual magnetosomes are assemblies of magnetosomes in which such alignment
23 does not take place. The chains of magnetosomes differ from the individual magnetosomes by their
24 coating. Using infra-red measurements, it has been shown that the chains of magnetosomes were
25 coated by a mixture of lipids and proteins whereas the individual magnetosomes were only coated by
26 lipids, [7]. Most probably due to different coatings, the chains of magnetosomes were found to have
27 a zeta potential (-22 mV at pH 7), which differs from that of the individual magnetosomes (+ 10 mV at
28 pH 7), [7]. The magnetic anisotropy of these two types of magnetosomes was studied by depositing a
29 suspension of these two types of magnetosomes on a substrate under the application of a magnetic
30 field, [45]. Magnetic anisotropy was evaluated by measuring the hysteresis loops of these two types
31 of magnetosomes for a magnetic field applied either parallel or perpendicular to the direction of the
32 alignment and by measuring the difference in coercivity and remanent magnetization between these
33 two field configurations. A larger magnetic anisotropy was found for the chains of magnetosomes
34 than for the individual magnetosomes. This comes from the better alignment of the easy axes in
35 chains of magnetosomes than in individual magnetosomes, [45]. The larger magnetic anisotropy of
36 the chains of magnetosomes compared with that of the individual magnetosomes could be another
37 factor responsible for their lower tendency to aggregate. The chains of magnetosomes possess
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 advantageous properties for medical applications due to their low level aggregation. Such property
4
5 results in high cellular internalization and in uniform tumor distribution. It makes the chains leave the
6
7 tumor more rapidly than the individual magnetosomes or chemically synthesized nanoparticles. It
8
9 also results in a percentage of chains eliminated in the feces following intra-tumoral administration,
10
11 which is larger than that obtained with individual magnetosomes, [6].
12

13
14 *Conclusion:*

15
16
17 In conclusion, we have reviewed the most recent data published on the use of magnetosomes for
18
19 magnetic hyperthermia treatment of tumors. Studies report that it is possible to produce
20
21 magnetosomes in large quantity (150 mg/liter/day) and to purify the magnetosomes in such a way
22
23 that cytotoxicity is avoided. The acute toxicity of the magnetosomes was found to be low with rats
24
25 surviving up to a quantity of magnetosomes administered of 480 mg per Kg of animal. Suspensions of
26
27 magnetosomes heated under the application of an alternating magnetic field yield high loss power
28
29 per cycle of 5-11 J/Kg_{Fe}, suggesting that the magnetosomes are good candidates for magnetic
30
31 hyperthermia treatments of tumors. Moreover, a proof of concept of a therapy using bacterial
32
33 magnetosomes as heating sources has been carried out on breast tumors xeno-grafted under the
34
35 skin of mice. It has revealed that it was possible to completely eradicate the xeno-grafted tumors
36
37 using this technique. Finally, two different types of magnetosomes have been studied, those
38
39 organized in chains, which possess cristallographic directions aligned in the direction of the chain
40
41 elongation and those organized as individual magnetosomes, which do not possess such alignment of
42
43 their cristallographic directions. It has been shown that the chains of magnetosomes produce the
44
45 best therapeutic results, mainly because of their low level of aggregation, which results in high
46
47 cellular internalization and uniform distribution throughout the tumor.
48
49
50
51
52
53
54
55
56
57
58
59
60

FIGURES:

Figure 1: Transmission electron microscopy images of whole MTB, (a), chains of magnetosomes isolated from MTB, (b), and individual magnetosomes detached from the magnetosome chains by a heat and SDS treatment, (c).

Figure 2: (a) The set-up used to carry out the treatment of the mice by positioning the mice inside the copper coil and by applying an alternating magnetic field. (b) The measurement of the temperature during the treatment. Photographs of the mice treated with a suspension containing chains of magnetosomes, (c), individual magnetosomes, (d), or superparamagnetic iron oxide nanoparticles (SPION), (e).

Figure 3: (a) The set-up used to expose a suspension containing chains of magnetosomes mixed with MDA-MB-231 cells to an alternating magnetic field of average magnetic field strength of ~ 20 mT and frequency of 198 kHz. A photograph showing this suspension placed next to a magnet before the application of the alternating magnetic field, (b), or after the application of the alternating magnetic field during 5 minutes, (c). Micrographs of MDA-MB-231 cells incubated with a suspension containing chains of magnetosomes during three minutes, (d), or 24 hours, (e).

Figure 4: Micrograph of a tumor tissue collected after the administration of the bacterial magnetosomes and three applications of an alternating magnetic field of average strength (20 mT) and frequency of 198 kHz for 20 minutes. The bacterial magnetosomes administered were individual magnetosomes, (a), or chains of magnetosomes, (b), (c). (c) is an enlargement of (b) and shows bacterial magnetosomes internalized within tumor cells.

REFERENCES:

1. Jordan A, Scholz R, Maier-Hauff K, K.H. Van Landeghem F, Waldoedner N, Teichgraeber U, Pinkernelle J, Bruhn H, Neumann F, Thiesen B, von Deimling A, Felix R, The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma, *Journal of NeuroOncology* 2006; 78: 7-14.
2. Ito A, Tanaka K, Kondo K, Shinkai M, Honda H, Matsumoto K, Saida T, Kobayashi T, Tumor regression by combined immunotherapy and hyperthermia using magnetic nanoparticles in an experimental subcutaneous murine melanoma, *Cancer Science* 2003; 94: 308-313.
3. Zhao Q, Wang L, Cheng R, Mao L, Arnold R D, Howerth E W, Chen Z G, Platt S, Magnetic Nanoparticle-Based Hyperthermia for Head and Neck Cancer in Mouse Models, *Theranostics* 2012; 2: 113-121.
4. Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A, Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme, *Journal of Neurooncology* 2011; 103: 317-324.
5. Bazylnski D A, Frankel R B, Magnetosome formation in prokaryotes, *Nature Reviews Microbiology* 2004; 2: 217-230.
6. Alphandéry E, Faure S, Seksek O, Guyot F, Chebbi I, Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy, *ACS Nano* 2011; 5: 6279-62296.
7. Alphandéry E, Guyot F, Chebbi I, Preparation of chains of magnetosomes, isolated from *Magnetospirillum magneticum* AMB-1 magnetotactic bacteria, yielding efficient treatment of

- 1
2
3 tumors using magnetic hyperthermia, International Journal of hyperthermia 2012; 434: 444-
4
5 452.
6
7
- 8 8. Sun J-B, Zhao F, Tang T, Jiang W, Tian J-S, Li J-L, High-yield growth and magnetosome
9 formation by *Magnetospirillum gryphiswaldense* MSR-1 in an oxygen-controlled fermentor
10 supplied solely with air, Appl. Microbiol. Biotechnol. 2008; 79: 389-397.
11
12
- 13 9. Liu Y, Li G R, Jiang W, Li Y, Li L J, Large-scale production of magnetosomes by chemostat
14 culture of *Magnetospirillum gryphiswaldense* at high cell density, Microbial Cell Factories
15 2010; 9:99.
16
17
- 18 10. Zhang Y, Zhang X, Jiang W, Li Y, Li J, Semicontinuous culture of *Magnetospirillum*
19 *gryphiswaldense* MSR-1 cells in an autofermentor by nutrient-balanced and isosmotic
20 feeding strategies, Applied and Environmental Microbiology 2011; 77: 5851-5856.
21
22
- 23 11. Heyen U, Schüler D, Growth and magnetosome formation by microaerophilic
24 *Magnetospirillum* strains in an oxygen-controlled fermentor, Appl. Microbiol. Biotechnol.
25 2003; 61: 536-544.
26
27
- 28 12. Matsunaga T, Tadokora F, Nakamura N, Mass culture of magnetic bacteria and their
29 application to flow type immunoassays, IEEE Transactions on magnetic 1990; 26: 1557-1559.
30
31
- 32 13. Matsunaga T, Tsujimura N, Kamiya S, Enhancement of magnetic particle production by
33 nitrate and succinate fed-batched culture of *Magnetospirillum* sp. AMB-1, Biotechnology
34 techniques 1996; 10: 495-500.
35
36
- 37 14. Yang C-D, Takeyama H, Tanaka T, Matsunaga T, Effects of growth medium composition, iron
38 sources and atmospheric oxygen concentrations on production of luciferase-bacterial
39 magnetic particle complex by a recombinant *Magnetospirillum magneticum* AMB-1, Enzyme
40 and Microbils Technology 2001 ; 29 : 13-19.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 15. Alphandéry E, Amor M, Guyot F, Chebbi I, The effects of iron-chelating agents on
4
5 Magnetospirillum magneticum strain AMB-1: stimulated growth and magnetosome
6
7 production and improved magnetosome heating properties, Appl. Microbiol. Biotechnol.
8
9 2012; 96: 663-670.
10
11
12 16. Philipse A P, Maas D, Magnetic colloids from magnetotactic bacteria: chain formation and
13
14 colloidal stability, Langmuir 2002; 18: 9977-9984.
15
16
17 17. Sun J-B, Duan J-H, Dai S-L, Ren J, Guo L, Jiang W, Li Y, Preparation and anti-tumor efficiency
18
19 evaluation of doxorubicin-loaded bacterial magnetosomes: magnetic nanoparticles as drug
20
21 carriers isolated from *Magnetospirillum gryphiswaldense*, Biotechnology and Bioengineering
22
23 2008; 101: 1313-1320.
24
25
26
27 18. Taoka A, Asada R, Sasaki H, Anzawa K, Wu L F, Fukumori Y, Spatial localizations of Mam22
28
29 and Mam12 in the magnetosomes of *Magnetospirillum magnetotacticum*, Journal of
30
31 bacteriology 2006; 188: 3805-3812.
32
33
34 19. Matsunaga T, Maeda Y, Yoshino T, Takeyama H, Takahashi M, Ginya H, Aashina J, Tajima H,
35
36 Fully automated immunoassay for detection of prostate-specific antigen nano-magnetic
37
38 beads and micro-polystyrene bead composites, 'Beads on Beads', Analytica Chimica Acta
39
40 2007 ; 597 : 331-339.
41
42
43
44 20. Grünberg K, Müller E-C, Otto A, Reska R, Linder D, Kube M, Reinhardt R, Schüler D,
45
46 Biochemical and proteomic analysis of the magnetosome membrane in *Magnetospirillum*
47
48 *gryphiswaldense*, Applied and Environmental Microbiology 2004; 70: 1040-1050.
49
50
51 21. Xiang L, Wei J, Jianbo S, Gulli W, Feng G, Ying L, Purified and sterilized magnetosomes from
52
53 *Magnetospirillum gryphiswaldense* MSR-1 were not toxic to mouse fibroblasts in vitro,
54
55 Letters in Applied Microbiology 2007; 45: 75-81.
56
57
58
59
60

- 1
2
3 22. Guo F, Liu Y, Chen Y, Tang T, Jiang W, Li Y, Li J, A novel rapid and continuous procedure for
4 large-scale purification of magnetosomes from *Magnetospirillum gryphiswaldense*, *Appl.*
5 *Microbiol. Biotechnol.* 2011; 90: 1277-1283.
6
7
8
9
10 23. Tang T, Zhang L, Gao R, Dai Y, Meng F, Li Y, Fluorescence imaging and targeted distribution of
11 bacterial magnetic particles in nude mice, *Appl. Microbiol. Biotechnol.* 2012; 94: 495-503.
12
13
14 24. Kobayashi A, Kirschvink J, Nash C Z, Kopp R E, Sauer D A, Bertani L E, Voorhout W F, Taguchi
15 T, Experimental observation of magnetosome chain collapse in magnetotactic bacteria:
16 Sedimentological paelomagnetic, and evolutionary implications, *Earth and Planetary Science*
17 *Letters* 2006; 245: 538-550.
18
19
20
21
22
23 25. Grünberg K, Wawer C, Tebo B M, Schüler D, A large gene cluster encoding several
24 magnetosome proteins is conserved in different species of magnetotactic bacteria, *Applied*
25 *and Environmental Microbiology* 2001; 67: 4573-4582.
26
27
28
29
30
31 26. Sun J-B, Duan J-H, Dai S-L, Ren J, Zhang Y-D, Tian J-S, Li Y, In vitro and in vivo antitumor
32 effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: The
33 magnetic bio-nanoparticles as drug carriers, *Cancer letters* 2007; 258: 109-117.
34
35
36
37
38
39 27. Gorby Y A, Beveridge T J, Blakemore R P, Characterization of the bacterial magnetosome
40 membrane, *Journal of bacteriology* 1988; 170: 834-841.
41
42
43
44 28. Alphandéry E, Ngo A T, Lefèvre C, Lisiecki I, Wu L F, Pileni M P, Difference between the
45 magnetic properties of the magnetotactic bacteria and those of the extracted chains of
46 magnetosomes: Influence of the distance between the chains of magnetosomes, *J. Phys.*
47 *Chem C* 2008; 112: 12304-12309.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 29. Sun J, Tang T, Duan J, Xu P-X, Wang Z, Zhang Y, Wu L, Li Y, Biocompatibility of bacterial
4 magnetosomes: Acute toxicity, immunotoxicity and cytotoxicity, *Nanotoxicology* 2010; 4:
5 271-283.
6
7
8
9
10 30. Alphandéry E, Carvollo C, Menguy N, Chebbi I, Chains of cobalt doped magnetosomes
11 extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field
12 cancer therapy, *Journal of physical Chemistry C* 2011; 115: 11920-11924.
13
14
15
16
17 31. Guo F F, Yang W, Jiang W, Geng S, Peng T, Li J L, Magnetosomes eliminate intracellular
18 reactive oxygen species in *Magnetospirillum gryphiswaldense* MSR-1, *Environmental*
19 *Microbiology* 2012; 14: 1722-1729.
20
21
22
23
24
25 32. Unpublished data. Suspensions magnetosomes were administered intravenously to mice.
26 They were observed in the feces of these mice collected after the administration by
27 transmission electron microscopy.
28
29
30
31
32 33. Liu R-T, Liu J, Tong J-Q, Tang T, Kong W-C, Wang X-W, Li Y, Tang J-T, Heating effect and
33 biocompatibility of bacterial magnetosomes as potential materials used in magnetic fluid
34 hyperthermia, *Progress in Natural Science: Materials International* 2012; 22: 31-39.
35
36
37
38
39 34. Sun J-B, Wang Z-L, Duan J-H, Ren J, Yang X-D, Dai S-L, Li Y, Targeted distribution of bacterial
40 magnetosomes isolated from *Magnetospirillum gryphiswaldense* MSR-1 in healthy Sprague-
41 Dawley rats, *Journal of Nanoscience and Nanotechnology* 2009; 9: 1881-1885.
42
43
44
45
46 35. Lacava L M, Garcia V A P, Kückelhaus S, Azevedo R B, Sadeghiani N, Buske N et al, Long-term
47 retention of dextran-coated magnetite nanoparticles in the liver and spleen, *J. Magn. Magn.*
48 *Mater.* 2004; 272: 2434-2435.
49
50
51
52
53 36. Timko M, Dzarova A, Skumiel A, Jozefcak A, Hornowski T, Gojzewski H, Zavisova V, Koneracka
54 M, Sprincova A, Strebak O, Kopcansky P, Tomasovicova N, Magnetic properties and heating
55
56
57
58
59
60

- 1
2
3 effect in bacterial magnetic nanoparticles, Journal of Magnetism and Magnetic Materials
4
5 2009; 321: 1521-1524.
6
7
- 8 37. Timko M, Molcan M, Hashim A, Skumiel A, Muller M, Gojzewski H, Jozefcak A, Kovac J, Rajnak
9
10 M, Makowski M, Kopcansky P, Hyperthermic effect in suspension of magnetosomes prepared
11
12 by various methods, IEE Transactions on magnetic 2013; 49: 250-254.
13
14
- 15 38. Hergt R, Dutz S, Roder M, Effects of size distribution on hysteresis losses of magnetic
16
17 nanoparticles for hyperthermia, Journal of Physics condensed matter 2008; 20: 385214.
18
19
- 20 39. Hergt R, Hiergeist R, Zeisberger M, Schüler D, Heyen U, Hilger I, Kaiser W, Magnetic
21
22 properties of bacterial magnetosomes as potential diagnostic and therapeutic tools, Journal
23
24 of Magnetism and magnetic materials 2005; 293: 80-86.
25
26
- 27 40. Dutz S, Hergt R, Mürbe J, Müller R, Zeisberger M, Andrä W, Töpfer J, Bellemann M E,
28
29 Hysteresis losses of magnetic nanoparticle powders in the single domain size range, Journal
30
31 of Magnetism and magnetic materials 2007; 308: 305-312.
32
33
- 34 41. Alphandéry E, Faure S, Raison L, Duguet E, Howse P A, Bazylinski D A, Heat production by
35
36 bacterial magnetosomes exposed to an oscillating magnetic field, Journal of physical
37
38 chemistry C 2011; 115: 18-22.
39
40
- 41 42. Rosensweig R E, Heating magnetic fluid with alternating magnetic field, J. Magn. Magn.
42
43 Mater. 2002; 252: 370-374.
44
45
- 46 43. Scheffel A, Gruska M, Faivre D, Linaroudis A, Grumann P, Plitzko J M et al, An acidic protein
47
48 aligns magnetosomes along a filamentous structure in magnetotactic bacteria, Nature 2006;
49
50 440: 110-114.
51
52
53
54
55
56
57
58
59
60

- 1
2
3 44. Alphandéry E, Chebbi I, Faure S, Treatment of cancer or tumor induced by the release of heat
4
5 generated by various chains of magnetosomes extracted from magnetotactic bacteria and
6
7 submitted to an alternative magnetic field, Patent WO2011/061259.
8
9
10 45. Alphandéry E, Ding Y, Ngo A T, Wang Z L, Wu L F, Pileni M P, Assemblies of Aligned
11
12 Magnetotactic Bacteria and Extracted Magnetosomes: What is the Main Factor Responsible
13
14 for the Magnetic Anisotropy?, ACSNANO 2009; 3: 1539-1547.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




FIG. 1

Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




FIG. 2

Review Only




FIG. 3

Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




FIG. 4

For Peer Review Only